Publications by authors named "M G van Vonderen"
Introduction: A major knowledge gap in the treatment of complicated bacteraemia (SAB) is the optimal duration of antibiotic therapy. Safe shortening of antibiotic therapy has the potential to reduce adverse drug events, length of hospital stay and costs. The objective of the SAFE trial is to evaluate whether 4 weeks of antibiotic therapy is non-inferior to 6 weeks in patients with complicated SAB.
View Article and Find Full Text PDFArticle Synopsis
- The COVIH study investigated the effects of an additional mRNA-1273 COVID-19 vaccination on immune responses in 1154 people living with HIV, particularly focusing on those with reduced antibody levels after their initial vaccinations.
- Results showed that 97% of participants significantly increased their antibody levels, with reported increases from 35 to 4317 binding antibody units per mL following the booster shot.
- The study concluded that the extra mRNA-1273 vaccination effectively enhanced immune responses, including T and B cell activation, in individuals who previously displayed weak responses to COVID-19 vaccines.
Background: Vaccines can be less immunogenic in people living with HIV (PLWH), but for SARS-CoV-2 vaccinations this is unknown. In this study we set out to investigate, for the vaccines currently approved in the Netherlands, the immunogenicity and reactogenicity of SARS-CoV-2 vaccinations in PLWH.
Methods And Findings: We conducted a prospective cohort study to examine the immunogenicity of BNT162b2, mRNA-1273, ChAdOx1-S, and Ad26.
Introduction: The aim of this study was to determine the efficacy of early tocilizumab treatment for hospitalized patients with COVID-19 disease.
Methods: Open-label randomized phase II clinical trial investigating tocilizumab in patients with proven COVID-19 admitted to the general ward and in need of supplemental oxygen. The primary endpoint of the study was 30-day mortality with a prespecified 2-sided significance level of α = 0.